CARsgen Therapeutics
Suite 401, Building 3, 466 Yindu Road
Xuhui District
Shanghai
200231
United States
Tel: 86-21-54489928
Fax: 86-21-54489926
Website: http://www.carsgen.com/
Email: info@carsgen.com
52 articles about CARsgen Therapeutics
-
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.
5/18/2023
CARsgen Therapeutics Holdings Limited announced that CARsgen has initiated patient enrollment for Phase 2 of the clinical trial for CT041 in the U.S., for the treatment of CLDN18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies.
-
CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer
5/5/2023
CARsgen Therapeutics Holdings Limited announced that AB011 in combination with atezolizumab monoclonal antibody, Roche's PD-L1 checkpoint inhibitor, along with chemotherapy achieved IND clearance from the CDE for first-line treatment Claudin18.2 positive unresectable locally advanced, recurrent or metastatic gastric cancer/gastroesophageal junction cancer.
-
CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer
4/20/2023
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) announced that CT041, an autologous CAR T-cell product candidate against the protein Claudin18.2 (CLDN18.2), has achieved IND clearance from the National Medical Products Administration (NMPA) for the postoperative adjuvant therapy of CLDN18.2 positive pancreatic cancer (PC).
-
CARsgen Announced 2022 Annual Results and Business Updates
3/22/2023
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 Annual Results.
-
CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI
1/20/2023
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) announces that a poster presentation highlighting the Phase 1 preliminary results of a recombinant humanized anti-claudin18.2 monoclonal antibody (AB011), as monotherapy and combination therapy, for patients with advanced solid tumors was presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium ("ASCO GI"), in San Francisco, California, during January 19-21, 2023.
-
CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China
1/16/2023
CARsgen Therapeutics Holdings Limited and Huadong Medicine today announced a collaboration for the commercialization of CARsgen's BCMA CAR-T product CT053 in mainland China.
-
CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting
12/12/2022
CARsgen Therapeutics Holdings Limited announces that at the 2022 American Society of Hematology (the "ASH") Annual Meeting, the Company presented a poster with the results of the phase II LUMMICAR STUDY 1 clinical trial of zevorcabtagene autoleucel.
-
CARsgen Appoints Dr. Sylvie Peltier as Senior Vice President of Global Regulatory Affairs
10/31/2022
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31st, 2022.
-
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA
10/18/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for zevorcabtagene autoleucel ("zevor-cel," R&D code: CT053), a fully human, autologous BCMA CAR T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (R/R MM).
-
The 7th Annual CAR-TCR Summit is ongoing in Boston, with more than 1,000 experts in CAR and TCR technologies attending. Here’s a look at some of the latest research and data being presented.
-
CARsgen Presents North America Phase 2 Updates for CT053 BCMA CAR T at the 7th Annual CAR-TCR Summit
9/21/2022
CARsgen Therapeutics Holdings Limited announces that at the 7th Annual CAR-TCR Summit, in Boston, Massachusetts, the Company gave an oral presentation on the North America Phase 2 clinical trial of zevorcabtagene autoleucel.
-
CARsgen Releases the First Clinical Batch of CAR T Cells from its RTP GMP Manufacturing Facility in North Carolina
9/2/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), announces that the company’s Current Good Manufacturing Practice (CGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America (“The RTP GMP Manufacturing Facility”) has started GMP production of autologous CAR T-cell products and successfully released the first GMP batch for the clinical trials.
-
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline
8/24/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022 Interim Results.
-
CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.
-
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
6/6/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
5/10/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which is one of the top international medical journals in the Nature Portfolio (2-year Impact Factor of 53.44).
-
CARsgen Therapeutics Opens New U.S. cGMP Facility for CAR T Production
2/21/2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies announced that its current Good Manufacturing Practices (cGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America ("The RTP Manufacturing Facility") has successfully passed the official inspections by local government.
-
CARsgen Therapeutics to Celebrate the Completion of Its cGMP Commercial Manufacturing Facility with Design and Construction Partner, CRB
2/21/2022
CARsgen Therapeutics, a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the grand opening of the newly completed 37,000-ft2 clinical and early-stage commercial manufacturing facility.
-
CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting
12/13/2021
CARsgen Therapeutics Holdings Limited today announces that at the 2021 American Society of Hematology ("ASH") Annual Meeting, the Company presented two posters with study results for CT053, an autologous CAR T-cell product candidate against B-Cell Maturation Antigen (BCMA).